Inside Remdesivir puzzle: 6 producers, little supply!
Demand fell to almost nil by January after the first wave of the pandemic in the country. Since there was no demand, most manufacturers stopped giving fresh orders for manufacturing
PB Jayakumar | May 3, 2021 | Updated 19:22 IST
Demand for Remdesivir fell to almost nil by January after the first wave of the pandemic in the country
Reduction in production due to less demand after the first wave of coronavirus and lack of vigil on the part of the Government to ensure stockpiling led to current Remdesivir crisis, say sources.
Gilead Life Sciences, the innovator of the re-purposed drug, had licensed six manufacturers in India to produce the drug. Most of them were dependent on contract manufacturers and their subsidiaries to make the product. Demand fell to almost nil by January after the first wave of the pandemic in the country. Since there was no demand, most manufacturers stopped giving fresh orders for manufacturing. Neith
Covid-19: Why is there a shortage of Remdesivir?- Business News businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
Container shortage, rising freight rates hit pharmaceutical exports
April 08, 2021
×
Shortage of empty containers, particularly reefer containers, and an almost 60 per cent surge in freight rates since October have hit export of pharmaceutical shipments from India.
The Indian Drug Manufacturers Association said that ports in southern India have borne the brunt of box shortage prevailing over the last 7-8 months and have urged the Commerce Ministry to intervene and help tide over the crisis.
The shortage of boxes, according to the association, has led to a rise in freight rates by almost 60 per cent.
SV Veerramani, past national president of the Association, told
Coronavirus pandemic underlined need for higher budget allocation for healthcare sector
India
Published: Sunday, January 24, 2021, 12:51 [IST]
New Delhi, Jan 24: The COVID-19 pandemic has emphasised the key role of healthcare in the lives of people, underlining the importance of higher budget allocation for improving the healthcare infrastructure in the country, sectoral players said.
The pharma sector which has played a leading role as the pharmacy of the world said it expects support and incentives especially for research & development and innovation in the coming budget. The pandemic has completely changed the dynamics of the Indian healthcare ecosystem, NATHEALTH President and Apollo Hospitals Executive Vice-Chairperson Preetha Reddy told PTI.